Brain-Controlled Lower-Limb Prosthesis Market Report 2026

The brain-controlled lower-limb prosthesis market size has grown rapidly in recent years. It will grow from $0.98 billion in 2025 to $1.13 billion in 2026 at a compound annual growth rate (CAGR) of 15.8%. The growth in the historic period can be attributed to advancements in myoelectric prosthetics, increasing incidence of limb loss, early adoption of microprocessor-controlled limbs, expansion of rehabilitation infrastructure, improvements in prosthetic material science.

The brain-controlled lower-limb prosthesis market size is expected to see rapid growth in the next few years. It will grow to $2.05 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to increasing demand for brain-controlled mobility solutions, rising integration of AI and machine learning in prosthetics, expansion of personalized prosthetic fitting technologies, growing adoption of smart rehabilitation platforms, increasing insurance coverage for advanced prosthetic systems. Major trends in the forecast period include increasing adoption of AI-controlled prosthetic gait systems, rising use of multi-modal neural signal integration, growing demand for adaptive and self-learning prosthetic limbs, expansion of sensory feedback enabled prostheses, enhanced focus on natural mobility restoration.

The rising incidence of diabetes-related amputations is anticipated to drive the expansion of the brain-controlled lower-limb prosthesis market in the coming years. Diabetes-related amputations are surgical interventions to remove a portion of the lower limb, which become necessary due to complications arising from long-term, poorly managed diabetes. The increasing occurrence of diabetes-related amputations results from inadequate glycemic control, which accelerates vascular damage, neuropathy, and chronic foot ulcers that often develop into severe infections and tissue loss. A brain-controlled lower-limb prosthesis assists individuals with diabetes-related amputations by restoring intuitive mobility and balance via direct neural control, promoting safer gait, reducing the risk of secondary complications, and enhancing long-term independence. For example, in March 2025, the Office for Health Improvement and Disparities, a UK government agency, reported that in 2024, GP-recorded adult prevalence of type 2 diabetes in England rose to 7% among individuals aged 17 and above, up from 6.8% in March 2023. Consequently, the rising incidence of diabetes-related amputations is fueling growth in the brain-controlled lower-limb prosthesis market.

The increasing number of clinical trials is anticipated to drive the growth of the brain-controlled lower-limb prosthesis market moving forward. Clinical trials are carefully designed research studies conducted on human participants to assess the safety, efficacy, and effectiveness of new drugs, treatments, medical devices, or interventions. The rising volume of clinical trials is driven by the growing prevalence of chronic and lifestyle-related diseases, which heightens the demand for developing effective therapies and treatments. Clinical trials contribute to brain-controlled lower-limb prostheses by systematically evaluating their safety, performance, and real-world usability, enabling optimized designs and evidence-based adoption for users. For instance, in December 2024, the Association of the British Pharmaceutical Industry, a UK trade association, reported that in 2023, the total number of industry-initiated clinical trials in the UK increased to 426, up from 411 trials in 2022, continuing growth for the second consecutive year. Therefore, the rising number of clinical trials is supporting the expansion of the brain-controlled lower-limb prosthesis market.

The expanding aging population is expected to drive growth of the brain-controlled lower-limb prosthesis market in the foreseeable future. An aging population is a demographic trend in which the proportion of older individuals within a population rises due to declining birth rates and increased life expectancy. The growing aging population is primarily attributed to longer life spans, as improvements in healthcare, nutrition, and living standards enable individuals to survive into older age. Brain-controlled lower-limb prostheses enhance the lives of older adults by restoring mobility and independence through intuitive neural control, improving their quality of life, and reducing reliance on caregivers. For example, in July 2024, the UK Parliament's House of Commons Library reported that in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is projected to reach 22.1 million by 2072, accounting for 27% of the population. Therefore, the expanding aging population is driving growth in the brain-controlled lower-limb prosthesis market.

Major companies operating in the brain-controlled lower-limb prosthesis market are Ottobock SE And Co. KGaA, Össur hf., Blatchford Limited, Fillauer Companies Inc., College Park Industries Inc., Exiii Inc., Advanced Arm Dynamics Inc., Open Bionics Ltd., BrainRobotics Inc., Blackrock Neurotech Inc., Coapt LLC, Hi-Tech Artificial Limbs Pvt. Ltd., Integrum AB, Liberating Technologies Inc., Limbitless Solutions Inc., Symbionic Inc., Unlimited Tomorrow Inc., Vincent Systems GmbH, Bionik Laboratories Corp., Credence Prosthetic Pvt. Ltd.

Tariffs are influencing the brain-controlled lower-limb prosthesis market by increasing costs of imported sensors, actuators, embedded processors, neural interface components, and lightweight structural materials. North America and Europe are particularly affected due to dependence on cross-border sourcing of high-performance electronics and precision components, while Asia-Pacific faces higher export manufacturing costs. These tariffs are raising prosthetic system prices and extending procurement cycles for clinics and rehabilitation centers. At the same time, they are supporting local assembly, regional component manufacturing, and innovation in cost-optimized bionic prosthetic solutions.

The brain-controlled lower-limb prosthesis market research report is one of a series of new reports that provides brain-controlled lower-limb prosthesis market statistics, including brain-controlled lower-limb prosthesis industry global market size, regional shares, competitors with a brain-controlled lower-limb prosthesis market share, detailed brain-controlled lower-limb prosthesis market segments, market trends and opportunities, and any further data you may need to thrive in the brain-controlled lower-limb prosthesis industry. This brain-controlled lower-limb prosthesis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Brain-controlled lower-limb prosthesis describes an advanced prosthetic leg solution that interprets neural signals obtained from the brain or peripheral nervous system to detect a user’s intended movements and convert them into accurate, real-time prosthetic control. This technology supports more natural mobility, balance, and adaptive gait by combining brain-computer interfaces, sensors, and intelligent control systems to closely replicate normal human motion.

The primary product types of brain-controlled lower-limb prostheses include myoelectric prosthesis, bionic prosthesis, hybrid prosthesis, and other product types. Myoelectric prosthesis refers to prosthetic limbs controlled by electrical signals generated by the user’s muscles to enable natural and intuitive movement. These prostheses employ technologies such as electroencephalography-based systems, electromyography-based systems, electrocorticography-based systems, and other technologies. They are applied across facilities such as hospitals, rehabilitation centers, prosthetic clinics, and other applications, and are used by end users including adults, pediatric, and elderly populations.

The brain-controlled lower-limb prosthesis market consists of sales of brain-controlled prosthetic legs, myoelectric lower-limb prostheses, bionic lower-limb prostheses, hybrid lower-limb prostheses, EEG-based prosthetic legs, EMG-based prosthetic legs, ECOG-based prosthetic legs, smart lower-limb prostheses, and adjustable prosthetic sockets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.